Filing Details
- Accession Number:
- 0001213900-19-006993
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-23 18:00:39
- Reporting Period:
- 2019-04-21
- Accepted Time:
- 2019-04-23 18:00:39
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1218683 | Wize Pharma Inc. | WIZP | Pharmaceutical Preparations (2834) | 880445167 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1720898 | Noam Danenberg | C/O Wize Pharma, Inc. 5B Hanagar Street Hod Hasharon L3 4527708 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-21 | 125,000 | $1.00 | 165,100 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Convertible Loans | Acquisiton | 2019-04-21 | 265,531 | $0.00 | 265,531 | $1.11 |
| Common Stock | Investment Rights | Acquisiton | 2019-04-21 | 94,382 | $0.00 | 94,382 | $1.33 |
| Common Stock | Series A Warrants | Acquisiton | 2019-04-21 | 125,000 | $0.00 | 125,000 | $1.10 |
| Common Stock | Series B Warrants | Acquisiton | 2019-04-21 | 125,000 | $0.00 | 125,000 | $1.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 265,531 | 2019-05-31 | No | 4 | P | Indirect | |
| 94,382 | 2019-04-21 | 2019-11-30 | No | 4 | P | Indirect |
| 125,000 | 2019-04-21 | No | 4 | P | Direct | |
| 125,000 | 2019-04-21 | No | 4 | P | Direct |
Footnotes
- Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time.
- Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities.
- Held by Mr. Danenberg's wholly-owned company Mobigo Inc.
- The Series A Warrants expire sixty (60) months after October 23, 2018.
- Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000.
- The Series B Warrants expire twenty (20) days following the later of (i) the public announcement of Phase II clinical data for LO2A or (ii) six (6) months following October 23, 2018.
Billionaire Hedge Funds
